Developmental Endothelial Locus-1, Platelet Count, and Soluble P-selectin in Overweight and Obese Subjects

Overweight and Obesity Clinical Trial

Official title:

Serum Levels of Developmental Endothelial Locus-1 and Its Relationship With Platelet Count and Soluble P-selectin in Overweight and Obese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05864079
• Other study ID #: DEL-1 and sP-sel in obesity
• Status: Completed
• Start date: June 1, 2023
• Est. completion date: April 1, 2024

Study information

• Verified date: June 2024
• Source: Aswan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational study aims to detect serum levels of Developmental Endothelial Locus-1 (DEL-1), Platelet Count, and Soluble P-selectin (sP-sel) in Overweight and Obese Subjects. The main questions it aims to answer are:

• Is there a difference in serum DEl-1 levels in overweight and obese subjects compared to normal subjects?

• Are there any relations between serum DEL-1 levels, sP-sel, and platelet count in overweight and obese subjects ?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: April 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male patients.

• Age (18-65) years.

• Healthy overweight and subjects.

Exclusion Criteria:

• Patients with cardiovascular diseases.

• Diabetic patients.

• Previous history of thrombo-embolic diseases.

• Patients with hyperthyroidism.

• Patients with any type of malignancy.

• Underlying hepatic or renal failure.

• Major surgery within 60 days.

Related Conditions & MeSH terms

• Overweight
• Overweight and Obesity

Intervention

Diagnostic Test:
• Platelet count
Platelet count in study groups
• Developmental endothelial locus-1 (DEL-1)
Serum DEL-1 in study groups
• soluble P-selectin (sP-sel)
Serum sP-sel in study groups

Locations

Country	Name	City	State
Egypt	Aswan University Hospital	Aswan

Sponsors (1)

Lead Sponsor	Collaborator
Aswan University Hospital

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Barale C, Russo I. Influence of Cardiometabolic Risk Factors on Platelet Function. Int J Mol Sci. 2020 Jan 17;21(2):623. doi: 10.3390/ijms21020623. — View Citation

Hajishengallis G, Chavakis T. DEL-1-Regulated Immune Plasticity and Inflammatory Disorders. Trends Mol Med. 2019 May;25(5):444-459. doi: 10.1016/j.molmed.2019.02.010. Epub 2019 Mar 15. — View Citation

Kwon CH, Sun JL, Kim MJ, Abd El-Aty AM, Jeong JH, Jung TW. Clinically confirmed DEL-1 as a myokine attenuates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes via AMPK/HO-1- pathway. Adipocyte. 2020 Dec;9(1):576-586. doi: 10.1080/21623945.2020.1823140. — View Citation

Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021 Mar;106(3):306-319. doi: 10.1111/ejh.13560. Epub 2020 Dec 13. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Platelet count	platelet count in venous blood samples in normal-weight, overweight, and obese subjects	6 months
Primary	Serum Developmental endothelial locus-1 levels	Serum developmental endothelial locus-1 in normal-weight, overweight, and obese subjects	6 months
Primary	Serum Soluble P-selectin levels	Serum Soluble P-selectin in normal-weight, overweight, and obese subjects	6 months